Eiko LifeSciences Limited (ELL), announced that it has acquired a 25.01 per cent stake in Reflux Pharmaceuticals Private Limited (RPPL), a pharmaceutical company that specialises in manufacturing and exporting active pharmaceutical ingredients (APIs) and intermediates.
The acquisition is part of ELL’s long-term strategic growth plan to diversify its portfolio and enter new markets.
“We are excited to join forces with Eiko LifeSciences Limited, a company with a proven track record and experience in the chemical sector. This acquisition will provide us with access to Eiko’s resources and network, which will help us accelerate our growth and innovation,” said Amitkumar Ghosh, Director of Reflux Pharmaceuticals Private Limited.
“We look forward to working together with Eiko to develop and market new products that will benefit our customers and society at large,” he added.